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1. Introduction 
Cryptococcus meningitis is the most severe form of cryptococcal infections that infects the 
brain parenchyma and sub-arachnoid space. It often progresses to fatal disease states when 
it goes untreated. The clinical presentation and disease course of cryptococcal infection is 
partially marked by changes that occur as a result of certain medical conditions including, 
use of glucocorticoids or other immunosuppressive drugs, diabetes, as well as the immune 
status of the host (Chuck, 1989; Dismukes, 1988). Mostly, the disease affects people with a 
compromised immune system and is found in people with advanced HIV infection and 
AIDS, with the major burden in South-East Asia and Africa (Mwaba, 2001; Maher, 1994; 
Moosa, 1997).   
The infection itself is caused by inhalation of a yeast-like round fungus with a 
polysaccharide capsule, known as Cryptococcal neoformans, and disseminates from the lungs. 
This fungus is the only pathogenic species of the genus Cryptococcus. Based on the capsule 
components four serotypes of C. neoformans (A, B, C and D) have been isolated, and the 
species is divided into two forms. Each serotype has different epidemiologic and pathogenic 
profile and their presence suggests an environmentally unfriendly atmosphere for people 
with a defective T cell function. Consequently, the common forms of C. neoformans that 
affect humans in Europe and parts of US is C. neoformans var neoformans, whereas in tropical 
areas such as the Far East, Africa and Australia, C. neoformans var gattii is the common form 
of cryptococcal infection (Gari-Toussaint,1996). C. neoformans var gattii is also thought to be 
ecologically resident on Eucalyptus trees (Ellis, 1990). An outbreak of Cryptococcosis in 
healthy humans and animals in Vancouver Island, Canada, and the subsequent isolation of 
C. neoformans var gattii in Washington and Oregon in the US, have now led to the 
understanding that this species is not restricted to tropical and sub-tropical climates alone 
(Datta, 2009). Rather it has a wider geographic distribution and can also thrive in temperate 
climates, as well as on species of trees other than Eucalyptus (Datta, 2009).  
Estimates indicate that worldwide, the burden of human cryptococcal infections ranges 
between 2 to 30 % and most infected patients have HIV/AIDS (Bicanic, 2006; French, 2002). 
An observation in the US in 1990 showed an increase to 5000 cases of cryptococcal meningitis 
infection in AIDS patients, compared to 300 cases in 1980 where half of these cases were 
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apparently without signs of immune suppression. In most nations, the effective adoption of 
antiretroviral therapy (ART) has led to a dramatic decrease in C. neoformans infection (Mirza, 
2003). In the US for instance, only 7 % of 2087 AIDS patients were found to have 
cryptococcoses whereas, in France the incidence dropped to 100 cases per year due to the 
introduction of triple antiretroviral therapy (Steven, 1989). In most parts of Africa however, 
the HIV epidemic led to the emergence and resurgence of many opportunistic infections 
including cryptococcal meningitis, mycobacteria, and cytomegalovirus. Lack of full access to 
ART in West Africa, resulted in cryptococcal meningitis becoming the second opportunistic 
infection to cause fatal disease, after mycobacteria in late stage HIV-infected patients 
(Okongo, 1998; Mwaba, 2001). For instance, between 1993 and 2006, C. neoformans accounted 
for 0.7 % of meningitis cases in Dakar, Senegal and 2.5 % at Point G Teaching Hospital in 
Mali (Soumare, 2005c; Coulibaly,2005).  By comparison, in 2006, 33 cases out of 3655 (0.9 %) 
hospitalized patients were found to be infected with cyptococcal meningitis in Cameroon 
(Mbuagbaw, 2006).  
In West Africa, diagnosis and treatment of cryptococcal meningitis is particularly faced with 
many difficulties including problems associated with efficiency of the healthcare system in 
these countries, poverty rate and educational status of those infected In the text that follows 
we summarize our understanding of the current challenges faced in the clinical diagnosis 
and treatment of this disease in this region, and make suggestions for future consideration.  
2. Epidemiology 
Although considerable efforts have been made to estimate the number of cases of cyptococcal 
meningitis and the percentage of those infected by Cryptococcal neoformans, there is still gaps 
in the knowledge of true estimates worldwide (Harrison, 2009). Current reports show that 
globally there are approximately 957, 900 cases of cyptococcal meningitis occurring every year, 
with majority of these infections found in areas of high HIV prevalence (Park, 2009). Of this 
figure, lack of adequate resources and funding, lack of early diagnosis, access to treatment 
and an ineffective distribution of ART results in the deaths of between 125,000 and 1,124,900 
cases shortly (3 months) after the infection (Park, 2009). In Uganda cyptococcal meningitis 
disease was found to cause 17 % of deaths among HIV-1-infected adults. In South Africa, 
between 13-44% of all deaths among 3 HIV-seropositive cohorts were reported to be 
associated with Cryptococcus neoformans infection (Bicanic, 2006). Globally, the incidence 
rates among people with HIV/AIDS are estimated to have risen to 12 % per year (Park, 
2009). Although HIV and other immune compromised individuals are implicated in this 
disease, reports indicate that there are a few cases of cyptococcal meningitis unrelated to HIV 
infection (Mirza, 2003).  
With the introduction of antiretroviral therapy (ART) rates in parts of the US decreased 
substantially from 23.6 per 1000 persons in 1993 to 1.6 per 1000 persons in the year 2000 
(Mirza, 2003) despite ongoing debates about the best timing to start ART. Though the 
optimal timing to initiate ART is not clear, it is known that current ART regimens and 
adherence to treatment are capable of suppressing viremia and thereby create an 
environment that enhances the functions of the immune system of patients undergoing 
treatment (Bisson, 2008; Zolopa, 2009; Makadzange, 2010). Consequently, the effective 
provision of ART has caused significant reductions in morbidity and mortality associated 
with severe immune suppression and has led to a reduction in the incidence of cyptococcal 
meningitis in HIV/AIDS patients. Such reduction is observed more in countries where there 
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is early access to HIV care and prophylaxis for cyptococcal meningitis as well as early 
diagnosis during initial stages of the infection.  
Current trends indicate that, most cases of cyptococcal meningitis found in Africa are among 
HIV-infected people with <100 cells/µl CD4 T cell count. Based on reported figures it is 
known that cyptococcal meningitis causes between 10-20 % deaths in Africa (French, 2002; 
Okongo, 1998; Park, 2009). Recently, a study in Malawi found cyptococcal meningitis to be the 
most common cause of meningitis disease with 40 % of cases from HIV-infected people. In 
West Africa, the disease is thought to be the most common opportunistic infection after 
mycobacteria. Data from West Africa are scanty due probably to a number of logistic 
problems and inefficiency with the health systems of the countries in this region, and as a 
result only a few of the cases in this region are reported here. Based on 2009 estimates 6 
countries can be ranked from first to sixth in terms of total numbers of cyptococcal meningitis 
cases in West Africa. At the top of this hierarchy is Senegal, followed by Burkina Faso, Cote 
d’Ivoire, Mali, Niger and Ghana, with approximately 0.7-2.5 % patients with AIDS having 
cryptococcal infection. 
 
Countries 
Years 
of Study 
Prevalence 
(%) 
Study 
Place 
Senegal 
(Soumare,2005) 
2005 3.9 - 32.5 
Infectious Diseases 
department of the 
Teaching Hospital of 
Fan 
Burkina Faso 
(Ki-
Zerbo,1996;Millogo,2004) 
1996 to 
2004 
1.16 - 20.5 
Internal medicine 
department of the 
Teaching Hospital of 
Ouagadougou 
Cote D’Ivoire 
(Ouedraogo,2007) 
2007 4.3 - 16.5 
Internal medicine and 
Infectious Diseases 
departments of the 
Teaching Hospital of 
Coccody 
Mali (Oumar,2008) 2008 8.3 
Infectious Diseases of 
the Teaching Hospital 
of Point-g, Bamako 
Niger (Seybou,2008) 2008 6.3 
National Hospital of 
Niamey 
Ghana (Frimpong,1998) 1998 0 
Microbiology 
Laboratory of Kumasi 
 
Note: Hierarchical list showing prevalence of Cryptococcal meningitis in West Africa obtained from 
different studies in this region. 
Table 1. Prevalence of Cryptococal meningitis in West Africa 
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3. Clinical & diagnostic profiles of Cryptococcal meningitis  
3.1 Clinical features 
Cryptococcal meningitis is an insidious disease. Following infection, cryptococcus spread to 
other organs particularly the central nervous system (CNS) which is the main site in either 
immune competent or immune suppressed individuals. Most patients present with no 
symptoms and only report fever and mild headaches as a result of intracranial pressure. 
Reports from Burkina Faso showed that between 1996 and 1998, the major symptoms in 
patients with cryptococcal infection were headache and fever with 3 out of 7 patients having 
no neck stiffness (Millogo, 2004). However, patients who reported with the same disease in 
2004 showed signs of neck stiffness, and headache.  For patients with HIV/AIDS, the 
meningitis may spread rapidly to many organs. Records from Cote d’Ivoire showed that a 
number of hospitalized patients on admission presented with nonspecific severe symptoms 
that were associated with progression of cryptococcal meningitis disease including weight loss 
(44-62 %), chronic diarrhea (22-44.2 %), fever (50-85 %), chronic coughs (14 %), coma, 
convulsions and neck stiffness (24.4-85%) (Eholie, 2000). In Mali, 15 of 17 (88.2 %) cases with 
cryptococcal meningitis had signs of some abnormality while the remaining 2 had isolated 
fever. Overall, 14 of these patients had HIV-1 infection and their median CD4 T cell counts 
were <200 cells/µl (range 1-237 cells/µl). The CD4 T cell counts for the remaining 3 immune 
competent individuals were between 347 and 899 cells/µl (Minta, 2008). In Senegal, 
common symptoms reported were headache (86.7 %), fever (73.3 %), vomiting (66.7 %) and 
general weight loss (75.6 %). Most patients also presented with neurological signs including 
altered consciousness, seizures, motor deficits (paraplegia, flaccid hemi paresis and 
paraparesis), cranial nerve problems and coma at different stages of the disease. In 27 
patients meningeal syndrome characterized by neck stiffness was followed by the presence 
of positive Kernig and/ or Bradzinski sign (Soumare, 2005a). There were no records for CD4 
T cell counts of the patients studied here (Soumare, 2005b; 2005c). Data from Niger showed 
that all 8 HIV-1-infected patients with cryptococcosis had both fever and headache, 3 of 8 
(37.5 %) had coma, and 1 (12.5 %) had seizures. The average CD4 T cell count for these 
patients was 41 cells/µl. 
3.2 Diagnostic features  
Diagnosis of the disease is easy and requires no sophisticated methods or equipment. 
Specimens for laboratory diagnosis are collected based on the symptoms presented by the 
patient. Although most body fluids, including cerebro-spinal fluid (CSF), sputum, 
bronchoalveolar lavage (BAL), bronchial washings, biopsy tissues, prostatic fluid and blood, 
can be used for performing the test, the most common specimen used in many areas around 
the world is CSF. In West Africa, diagnosis is commonly performed by microscopic 
examination of CSF for yeast cells. 
3.2.1 Direct microscopy 
The conventional method for laboratory diagnosis involves direct examination of CSF 
deposits by use of Indian ink/Nigrosin wet mount coloration to detect yeast cells. Direct 
microscopy of samples from HIV-infected individuals often yields positive results in 90% of 
cases (Desmet, 1989). It is more useful to perform blood culture for disseminated cases. To 
confirm diagnosis, CSF is cultured on Sabouraud agar plates for > 36 h. This allows cultures 
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to grow and the method can be utilized for evaluating disease burden by diluting aliquots of 
CSF and enumerating the number of colony-forming units for the fungal load in the 
specimen (Eholie, 2000; Ki-Zerbo, 1996; Millogo, 2004; Soumare, 2005c). With a little 
modification, the method can also be used for assessing efficacy of anticryptococcal 
regimens (Bicanic, 2009). 
3.2.2 Serology 
Some reports have indicated that, due to changes in the epidemiology of the infection, 
detection of small capsules of the antigen make recognition difficult with India ink staining 
(Bottone, 1986). A second method for diagnosing C. meningitis infection is therefore by use of 
latex agglutination test to detect cryptococcal polysaccharide capsular antigens of C. 
neoformans. This test can be performed on CSF and serum and there are commercially 
available kits (example Crypto-LA [International Biological Labs. Inc., Cranbury, N.J.], 
MYCO-Immune [American MicroScan, Mahwah, N.J.], and IMMY [Immuno-Mycologics, 
Inc., norman, Okla], or CALAS [Meridian Diagnostics Inc., Cincinnati, Ohio]) with high 
sensitivity and specificity for carrying out this test. In most AIDS or other severely immune 
compromised patients, it is not useful to perform antibody detection tests. 
 
Country Different Studies 
Diagnostic Methods 
Culture of 
CSF 
Serology 
Direct 
Microscopy 
Burkina Faso 
Ki-Zerbo, 1996 + - + 
Millogo, 2004 + - + 
Cote d’Ivoire 
Eholie, 1997 - + + 
Eholie, 2000 + + + 
Eholie, 2004 + + + 
Ouedraogo, 2007 + - + 
Mali 
Oumar, 2008 - - + 
Minta, 2008 + - + 
Senegal 
Soumare, 2005a + + + 
Soumare, 2005b + + + 
Soumare, 2005c + + + 
Niger Seybou, 2008 - + - 
Ghana Frimpong, 1998 + - + 
 
Note: (+) is Used and (-) not Used 
 
Table 2. Different Methods Used for Cryptococcus Diagnosis in West Africa 
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4. Therapeutic aspects 
Much progress has been made in the management of Cryptococcal meningitis in the 
developed world. For immune compromised patients with Cryptococcal meningitis three 
phases of therapy (induction for 2 weeks, consolidation for 8 weeks and maintenance for 
prolonged period) for receiving antifungal treatment have been suggested based on results 
from a clinical trial (van der Horst, 1997). Also, based on guidelines endorsed by the 
Infectious Diseases Society of America a higher dose of amphotericin B followed by 
fluconazole can be used to treat AIDS patients with cryptococcal meningitis. Of importance 
is that, although oral fluconazole is known to provide some initial relief from cryptococcal 
meningitis, it takes a longer duration to cleanse the cerebrospinal fluid of its fungal 
pathogens (Brouwer, 2004; Larsen, 1990; van der Horst, 1997).  
It is now known that use of fluconazole alone, for treatment of the disease in AIDS patients 
is not enough, and that other approaches such as the use of amphotericin B combined with 
flucytosine, as well as increased immunological responses due to the use of antiretroviral 
drugs, are also required (Larsen, 1990). Thus, for immune suppressed patients with 
cryptococcal meningitis, treatment regimens include < 1.0 mg/kg/day amphotericin B 
deoxycholate (AmB) given intravenously plus 100 mg/kg/day flucytosine for 2 weeks 
followed by 400 mg oral Fluconazole for 8 weeks. In most countries in Africa however, due 
to a number of reasons including, cost, lengthy regulatory approval to import antifungal 
drugs, difficulty of administration and blood monitoring of amphotericin B-based therapy 
to avoid toxicity, fluconazole is used as primary therapy for the treatment of the disease 
(Bicanic 2009;  Bicanic, 2005). Fluconazole causes fewer, less severe side effects, including 
skin rashes and liver enzyme abnormalities. Even with the use of fluconazole alone, 
problems with access to expert medical care and the management of complications of AIDS 
still exist in this region (Mwaba, 2001; Wertheimer, 2004). In most countries of West Africa 
fluconazole monotherapy was used. 
Some reports have suggested that initial monotherapy with fluconazole led to relapse of 
HIV-associated cryptococcal meningitis. To prevent relapses, most doctors recommend that 
people who have had cryptococcal meningitis take fluconazole daily. Other drugs used 
include intravenous amphotericin B taken weekly or biweekly (Jackson, 2010). 
Amphotericin B has many side effects, including kidney damage, high fever, low blood 
pressure, decreased numbers of red or white blood cells, nausea, vomiting, and chills. A 
newer formulation of the drug, in which the active compound is encased in a fatty 
substance, has been under study for a while and may have fewer side effects (Sharkey, 
1996). However, more research is needed to assess the safety and effectiveness of this new 
form of amphotericin B. Flucytosin also may cause serious side effects, including decreased 
numbers of red or white blood cells, liver damage, nausea, diarrhoea, seizures, abdominal 
discomfort, or rash. In Mali treatment with amphotericin B and fluconazole injection is 
known to have had such side effects in 13 out of 17 patients (Oumar, 2008). Before the 
administration of amphotericin B, patients were injected with chlorpromazine (one hour 
before) and acetylsalicylic acid (30 min earlier). Then the infusions of amphotericin B were 
followed by an infusion of between 1.5-2 liters of 0.9% saline. This procedure was to reduce 
adverse effects associated with the use of amphotericin B (Oumar, 2008). In immune 
competent people, treatment is done using injectable amphotericin B alone, or followed by 
infusion of fluconazole treatment for some cases. In other cases, patients received 
amphotericin B in association with injectable ceftriaxon (Minta, 2008).  
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In Senegal fluconazole alone was the most commonly used antifungal in at least 93% of 
cases. It was used together with amphotericin B in one case (Soumare, 2005c). Here, the 
treatment strategy was the administration of fluconazole at 400 to 800 mg/day by 
intravenous infusion for 8 weeks, followed by a maintenance dose of 200 mg daily for a 
month. The maintenance treatment was however, continued until the CD4 count rose above 
200 cells/µl for a period of 6 months (Soumare, 2005a). In Niger 3 out of 4 patients 
diagnosed in 2007 received monotherapy consisting of 400mg/day fluconazole (Seybou, 
2008).  The average duration of treatment was 25.2 days (range, 2-72 days). Although no 
HIV patients died during emergency periods, 165 cases (53%) were hospitalized and 147 
patients were allowed to return home after the emergency care (47%) (Tanon, 2006). In a 
patient aged 66 years, cognitive functions declined partly from the 10th day. The delirium in 
a second patient aged 49 years, declined by the 10th day, and complete neurological 
recovery was observed at 3 months (Kouame, 2007). Overall, hospital stay period lasted for 
25 days and between 1-50 days for those associated with cryptococcal meningitis. The 
severity of the prognosis was related to the combination of two or more opportunistic 
infections (Ouedraogo, 2007). In Burkina Faso, fluconazole was initially effective in two 
patients with a dose of 400mg/day, which was started on the eve of the death of a patient 
(Millogo, 2004). 
The paucity of prospective data on the management of cryptococcal meningitis in patients 
without AIDS is the most challenging aspect of formulating treatment guidelines, but the 
principles of induction, consolidation, and maintenance were still applied. For patients with 
a predisposition to renal dysfunction a combination antifungal therapy with a lipid 
formulation of amphotericin B plus flucytosine was generally indicated.  
5. Early diagnosis, Importance and challenges of ART initiation in the 
management of cryptococcal meningitis 
During HIV infection, because the CD4+ T cells are the primary target of the virus, 
progressive loss of these cells leads to increasing immunodeficiency and risk of 
opportunistic diseases, progression to AIDS and ultimately death (O’Brien, 1996) The 
resurgence of HIV in resource poor settings in Africa and the complications associated with 
management of AIDS has led to a number of deaths attributable to cryptococcal meningitis. 
The good news is that reduction in CD4 cells can be reversed with effective antiretroviral 
therapy early in the course of infection and slow down its spread (Bisson, 2008). Despite 
this, it is important to note that often some proportion of patients who start therapy when 
their CD4 T cell counts are below 100 cells/µl are unable to gain restoration of their cells 
with ART and therefore pose additional challenges in treatment (Kelley, 2009). In addition 
to an increase in CD4 cell count, early initiation of therapy also increases general immune 
function, is cost-effective and facilitates the reduction in a number of clinical events, 
including lowering of incidence or risk of opportunistic infections. And although a number 
of guidelines are available for early initiation of ART in patients with AIDS-defining 
illnesses, the implementation of these guidelines in itself is a further challenge for resource-
limited regions such as West Africa. Here, treatment poses additional financial burden 
because, under such guidelines ART will have to be provided for a large number of patients. 
Another concern is that, the use of ART comes with some complex challenges. Most notably 
is the possibility of developing immune reconstitution inflammatory syndrome (IRIS), a 
condition that occurs following rapid restoration of immune function after ART 
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Countries 
Different 
Studies 
Antifungal and adjuvant therapy 
AmB FCZ KTZ 
AmB ;
ASA 
FCZ; 
ASA 
AmB ;
FCZ 
 
AmB ;FCZ ; SS 
CPMZ 
 
Burkina 
Faso 
Ki-Zerbo, 
1996 
- + + - - - - 
Millogo,2
004 
- + - - - - - 
 
 
 
 
Cote 
D’Ivoire 
Eholie,199
7 
+ - - - - - - 
Eholie,200
4 
+ - - - - - - 
Ouattara,
2007 
- - - - + - - 
Ouedraog
o, 2007 
+ - - - - - - 
Mali 
Oumar,20
08 
- - - - - - + 
Minta,200
8 
+ - - - - + - 
 
Senegal 
Soumare, 
2005a 
- + - - - + - 
Soumare, 
2005b 
- + - - - - - 
N’diaye,2
008 
+ + - - - - - 
Niger 
Seybou, 
2008 
- + - - - - - 
Ghana 
Frimpong
, 1998 
No Treatment as they didn’t recovered the fungus 
 
(+) is Used and (-) not Used 
AmB : Amphotericin B ; FCZ : Fluconazol ; KTZ: Ketoconazole; CPMZ: Chlorpromazin; 
ASA: acetyl salicylic acid; SS: Saline solution 
 
Table 3. Treatment Regimens used for Cryptococcus in West Africa 
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administration. In South Africa, cryptococcal reconstitution disease was associated with 6 of 
22 deaths in a HIV-infected cohort within 3 months of starting ART (Bicanic, 2009; Lawn, 
2005). Recent data also suggests potential drug interactions between nevirapine-based ART 
and high levels of fluconazole and the handling of any toxicities associated with this 
interaction may pose additional management difficulties in the West African context 
(Manosuthi, 2007).  
6. The lethality of cryptococcal meningitis in West Africa 
Cryptococcal meningitis is a disease that has a high chance of causing death. In West Africa, 
reported deaths associated with this disease are between 42 and 80% (Sow, 1998; Millogo, 
2004, Eholie, 2000, Bissagnene, 1994, Ki-Zerbo, 1996, Soumare, 2005a, Kadjo, 2007, Oumar, 
2008). The disease progresses to fatal states quickly. In 80% of cases, patients died before day 
15 after hospitalization (Millogo, 2004, Seybou 2008). Such high mortality is correlated with 
an increased number of Cryptococcal pathogens similar to that seen with Mycobacterium 
tuberculosis (Eholié, 2000, Ouedraogo, 2007). One study noted that a lowered CSF glucose 
provides poor prognosis for Cryptococcal meningitis in West Africa (Ki-Zerbo, 1996). 
Pronounced immune deficiency and hematological abnormalities such as hyponatremia are 
also factors of poor prognosis (Eholié, 1997; Ki-Zerbo, 1996). Others noted that the lethality 
of the disease is significantly higher in patients with a CD4 T cell count below 20 cells/µl 
(Ki-Zerbo, 1996; Soumare, 2005a). Recent studies  in the region indicate that the lethality of 
Cryptococcal meningitis is significantly associated with delay in diagnosis and initiation of 
appropriate treatment as well as  non-compliance to drug therapy due to financial reasons 
(Eholié, 2000; Kadjo, 2007; Millogo, 2004; Ouattara, 2007; Oumar, 2008; Soumare, 2005b). The 
high lethality may also be due to inadequate treatment regimens used in the region (Oumar, 
2008, Soumare, 2005a, Kadjo, 2007). The high fatality rate found in most countries of West 
Africa could be due to the fact that people consult with end-stage disease.  
7. Conclusion  
Impaired immunity associated with HIV infection has led to many complications. Effective 
introduction of anti-retroviral therapy has played a significant role in the reductions of 
Cryptococcosis in HIV/AIDS patients in most developed nations. The resurgence of HIV in 
developing countries has however, exposed many inadequacies in the management and 
control of cryptococcal meningitis in West Africa and elsewhere. Inadequate resources and 
an ineffective distribution of ART in this region could lead those with HIV to be more at risk 
of infection with Cryptococcus species. For those already having Cryptococcus disease, lack 
of early diagnosis offers an environment to progress to more fatal disease states.  
Given that laboratory diagnosis of Cryptococcal meningitis is easy to perform and does not 
require extensive equipment, it is vital that the resources and capacity to perform this test is 
made available in centers of HIV care. An increasing number of studies have shown that 
relapses to initial treatment to cryptococcal disease is a possibility and can lead to further 
complications, including immune reconstitution inflammatory syndrome. Despite this 
knowledge, little is known of surveillance studies related to drug susceptibility to resistant 
cases of Cryptococcal meningitis in West Africa. More education at community and other 
grass root levels must be stepped up to increase awareness of the importance of early 
screening for Cryptococcus disease. In most resource-poor settings studied in West Africa, 
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the standard of care for HIV/AIDS patients with acute cryptococcal meningitis are 
dependent on availability of resources and access to anti-fungal drugs. Logically, as a first 
step, and if available it is necessary to sterilize the CSF of patients with amphotericin B, since 
this regimen is known to minimize resistance to fluconazole (Bicanic, 2006). As an 
alternative approach, it will be beneficial in this setting to give higher doses of fluconazole 
bearing in mind that better clinical and microbiological responses to fluconazole have been 
observed in some studies (Berry, 1992; Hossain, 2002). In addition, there is an urgent need 
for policy makers to step up capabilities for managing complications associated with HIV 
patients progressing to AIDS. Finally, given the impact of effective antiretroviral therapy in 
reducing HIV-associated morbidity and mortality it will be more supportive if in West 
Africa, governments and care-givers find easier alternative ways to reach patients with these 
drugs (ART) taking into consideration travel times to the health care centers which often 
deters patients from seeking care. Clearly, more work is needed in this region for the 
management of cryptococcal meningitis and includes a focus on effective diagnosis, 
therapeutic use of available medications and monitoring to avoid toxicity levels. 
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